Name: Top Laboratory Analytical Instruments Stocks in USA comparison snapshot
Creator: Fliar BI Prism

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1A · NYSE

Agilent

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1998Ankeny, Iowa$43.38B market cap

View full Companies Radar profile

49Cautious

Snapshot price$153.8as of page date

Monthly-close return-10.1%five-year window

FY2025 revenue$6.95BAGILENT TECHNOLOGIES, INC.

Net margin18.8%FY2025

P/E snapshot30.3xone ratio, not a verdict

Prism attention21.8%share across these five

Filing track recordRevenue, USD billions

+1.5%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.5%

52-week position82% through range

$108.3$163.8

News mentions10.7K

Community mentions571partial coverage

U.S.-scope patents9779

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability55/100
Market position30/100
Capital-event signal74/100
Innovation pulse5/100

Management signal

Leadership churn is flagged elevated; 11 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 48 M&A involvements, 12 asset-acquisition events and 20 contract events.

Innovation activity

Prism records 8 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2BRKR · Nasdaq

Bruker

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1960WILMINGTON$8.70B market cap

View full Companies Radar profile

47Cautious

Snapshot price$57.08as of page date

Monthly-close return-32.9%five-year window

FY2025 revenue$3.44BBRUKER CORP

Net margin-0.3%FY2025

P/E snapshot23.7xone ratio, not a verdict

Prism attention10.2%share across these five

Filing track recordRevenue, USD billions

+42.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.2%

52-week position78% through range

$28.53$65.30

News mentions5.0K

Community mentions131partial coverage

U.S.-scope patents1431

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position35/100
Capital-event signal36/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 34 M&A involvements, 13 asset-acquisition events and 9 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ILMN · Nasdaq

Illumina

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1993WILMINGTON$32.55B market cap

View full Companies Radar profile

44Cautious

Snapshot price$215.6as of page date

Monthly-close return-48.8%five-year window

FY2025 revenue$4.34BILLUMINA, INC.

Net margin19.6%FY2025

P/E snapshot40.1xone ratio, not a verdict

Prism attention62.2%share across these five

Filing track recordRevenue, USD billions

+34.1%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.6%

52-week position89% through range

$88.00$231.8

News mentions30.6K

Community mentions1.4Kpartial coverage

U.S.-scope patents11196

Prism InsightsWhat sits behind the readiness signal
Observed risk 10/100higher means more observed risk

Earnings signal70/100
Management stability55/100
Market position27/100
Capital-event signal52/100
Innovation pulse10/100

Management signal

Leadership churn is flagged elevated; 5 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 49 M&A involvements, 6 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 19 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TXG · Nasdaq

10X Genomics

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 2012Wilmington$8.02B market cap

View full Companies Radar profile

43Cautious

Snapshot price$61.54as of page date

Monthly-close return-63.1%five-year window

FY2025 revenue$0.64B10x Genomics, Inc.

Net margin-6.8%FY2025

P/E snapshot302.7xone ratio, not a verdict

Prism attention1.9%share across these five

Filing track recordRevenue, USD billions

+31.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.0%

52-week position90% through range

$11.16$66.94

News mentions915

Community mentions133partial coverage

U.S.-scope patents2575

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position8/100
Capital-event signal45/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 5 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5AVTR · NYSE

Avantor

A U.S.-listed issuer classified by the SEC in Laboratory Analytical Instruments

Founded 1904Radnor$9.86B market cap

View full Companies Radar profile

41Cautious

Snapshot price$14.58as of page date

Monthly-close return-63.0%five-year window

FY2025 revenue$6.55BAvantor, Inc.

Net margin-8.1%FY2025

P/E snapshot16.5xone ratio, not a verdict

Prism attention3.9%share across these five

Filing track recordRevenue, USD billions

-11.3%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -3.0%

52-week position84% through range

$7.26$15.93

News mentions1.9K

Community mentions87partial coverage

U.S.-scope patents327

Prism InsightsWhat sits behind the readiness signal
Observed risk 11/100higher means more observed risk

Earnings signal58/100
Management stability90/100
Market position21/100
Capital-event signal35/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 14 M&A involvements, 6 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 5 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Agilent

-10.1%

Bruker

-32.9%

Illumina

-48.8%

Avantor

-63.0%

10X Genomics

-63.1%

Latest revenue

USD billions, official filing scope shown on each company card.

Agilent

$6.95B

Avantor

$6.55B

Illumina

$4.34B

Bruker

$3.44B

10X Genomics

$0.64B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Illumina

19.6%

Agilent

18.8%

Bruker

-0.3%

10X Genomics

-6.8%

Avantor

-8.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Illumina

62.2%

Agilent

21.8%

Bruker

10.2%

Avantor

3.9%

10X Genomics

1.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized laboratory analytical instruments news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Illumina leads the conversation

It holds 62.2% of measured laboratory analytical instruments news attention and also carries the basket's largest revenue base at $4.34B.

Price path

Agilent leads the available price paths

Its monthly-close return is -10.1% for the five-year window. At the other end, 10X Genomics is -63.1% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Illumina has the widest latest margin

Its FY2025 net margin is 19.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Avantor shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 16.5x while its five-year window price return is -63.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · A

Agilent

10,749available Prism news records

Prism top themes

Earnings & financial performance

133

Price action & investor response

122

Capital allocation & transactions

110

Macro demand & rates

104

Leadership & governance

92

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-59.7%1,082 latest 12m vs 2,687 prior 12m

Machine-classified coverage tone

96.0% positive-1.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer biomarkers 45rf network analyzer 44earnings report 43lte-m 37rf spectrum analyzer 37biomarker discovery 36diagnostic biotechnology 355g advanced 35

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · BRKR

Bruker

5,033available Prism news records

Prism top themes

Price action & investor response

136

Earnings & financial performance

127

Capital allocation & transactions

55

Legal, arbitration & regulatory

33

Leadership & governance

20

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+3.1%757 latest 12m vs 734 prior 12m

Machine-classified coverage tone

91.7% positive-1.2 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

pharmacogenomics 43biomarker discovery 38stock performance 37earnings report 35stock price 31share price 30investor conference 27cancer biomarkers 24

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-11 · trend and themes shown through 2026-06

Areas of research · ILMN

Illumina

30,607available Prism news records

Prism top themes

Price action & investor response

199

Earnings & financial performance

156

Capital allocation & transactions

137

Legal, arbitration & regulatory

122

Leadership & governance

77

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-15.5%3,130 latest 12m vs 3,703 prior 12m

Machine-classified coverage tone

88.7% positive+9.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

tariff negotiations 221genome architecture 219pharmacogenomics 213antimicrobial resistance surveillance 208whole-genome duplication 184trade dispute mechanisms 136phylogenomic datasets 124microbiome modulation 124

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · TXG

10X Genomics

915available Prism news records

Prism top themes

Earnings & financial performance

57

Price action & investor response

52

Legal, arbitration & regulatory

11

Capital allocation & transactions

9

Leadership & governance

9

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.9%204 latest 12m vs 208 prior 12m

Machine-classified coverage tone

92.4% positive+14.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

patent litigation 25genome browser 18stem cell banking 17stock performance 11pharmacogenomics 10gene patents 9stem cell patents 9biological material patents 9

Keyword tag occurrences in available Prism news records.

Coverage: 2015-10-06–2026-06-19 · trend and themes shown through 2026-06

Areas of research · AVTR

Avantor

1,905available Prism news records

Prism top themes

Earnings & financial performance

121

Price action & investor response

91

Leadership & governance

69

Legal, arbitration & regulatory

46

Capital allocation & transactions

34

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+10.9%386 latest 12m vs 348 prior 12m

Machine-classified coverage tone

85.4% positive-6.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 39earnings report 38quarterly results 31stock price 27financial report 26annual earnings 25quarterly financials 25chemical pricing 21

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-12–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

A

Agilent

571 mentions

Stock and valuation

211

Products, pricing and logistics

84

Workplace and hiring

49

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 571 records remained after filtering.

BRKR

Bruker

131 mentions

Stock and valuation

25

Products, pricing and logistics

13

Workplace and hiring

4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 131 records remained after filtering.

ILMN

Illumina

1,396 mentions

Stock and valuation

616

Products, pricing and logistics

294

Workplace and hiring

116

Other company context

3

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,396 records remained after filtering.

TXG

10X Genomics

133 mentions

Stock and valuation

66

Products, pricing and logistics

17

Workplace and hiring

7

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 133 records remained after filtering.

AVTR

Avantor

87 mentions

Stock and valuation

39

Products, pricing and logistics

9

Workplace and hiring

7

Other company context

2

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 87 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

A

Agilent

through 2026-05-04

Earnings releases 55Leadership changes 28M&A 25Business contracts 11Company announcements 9

2026-05-04
Leadership changes
Agilent Technologies Inc. (NYSE: A ) today announced the appointment of Michael Buckner as chief legal officer, effective today.
2026-04-10
M&A
Bridgefront Capital LLC bought a new position in shares of Agilent Technologies during the third quarter valued at about $1,323,000.
2026-02-25
Earnings releases
Agilent Technologies' fiscal first-quarter 2026 revenue rose 7 percent year over year, while its life sciences and diagnostics business grew 5 percent, it reported after the close of the market on Wednesday.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BRKR

Bruker

through 2026-04-23

Earnings releases 37M&A 18Business contracts 7Asset acquisitions 6Listing / IPO 6

2026-04-23
M&A
XRF Scientific (ASX: XRF) is acquiring Bruker AXS SE’s Combustion Gas Analysis (CGA) business for USD 4.0 million upfront, expanding its product portfolio and bringing manufacturing to Australia.
2026-04-03
Leadership changes
Bruker has appointed Thierry Bernard to its board of directors.
2026-02-12
Earnings releases
Fiscal Year 2025 (FY25) Financial Results FY25 revenues were $3.44 billion , an increase of 2.1% from $3.37 billion in FY24.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ILMN

Illumina

through 2026-05-01

Leadership changes 72Regulatory 57Earnings releases 51Lawsuits 42Company announcements 37

2026-05-01
Earnings releases
Illumina’s Q1 net income was $134 million, or $.87 per share, compared to $131 million, or $.82 per share, in Q1 2025. Adjusted EPS was $1.15, beating analysts’ average EPS estimate of $1.05.
2026-04-03
Leadership changes
Additionally, the board has nominated David King to become a new member.
2026-02-03
Asset acquisitions
The decision to sell its short-read sequencing technology to Illumina, announced on Monday, puts Pacific Biosciences back to its long-read sequencing roots...

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TXG

10X Genomics

through 2026-02-13

Earnings releases 46Leadership changes 8Lawsuits 3Listing / IPO 3

2026-02-13
Earnings releases
For three months ended Dec. 31, 2025, 10x booked $166.0 million in total revenues, up less than 1 percent from $164.9 million a year ago.
2025-02-14
Listing / IPO
Pleasanton, Calif.-based 10x Genomics Inc. priced its initial public offering to raise $390 million and then immediately climbed in the first hours of trading.
2024-08-09
Leadership changes
the recent additions of Alan Mateo and Sarah Teichmann to our Board of Directors

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AVTR

Avantor

through 2026-05-01

Earnings releases 38Company announcements 20Leadership changes 9Lawsuits 5Asset acquisitions 3

2026-05-01
Earnings releases
Avantor (NYSE:AVTR) said first-quarter 2026 results came in ahead of internal expectations, driven by improved execution in its Bioscience & Medtech Products (BMP) segment and early progress from its “Revival” operational and commercial program.
2026-02-13
Company announcements
Avantor (NYSE:AVTR) executives outlined early progress on the company’s “Project Revival” initiative and provided 2026 guidance that management characterized as a transitional year focused on strengthening the business while tracking improvement primarily through organic revenue growth.
2026-01-01
Leadership changes
Avantor, Inc., a provider of products and services to customers in the life sciences industry, has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of executive vice president, strategy and corporate development, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Laboratory Analytical Instruments Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary laboratory analytical instruments news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

analytical laboratory instrument market

2 sources72.9% extraction confidence

2024 extracted base$171.56B

2030 extracted forecast$171.56B

Implied source CAGR7.6%

accelerating investment in biotechgrowing R&D in pharmaceuticalaging population

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Laboratory Analytical Instruments news pulse

7,952available Prism news records

Latest 12m volume+14.8%3473 vs 3024 records

Positive classified tone95.0%+4.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching analytical, instrument, laboratory. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

astronomical instrumentation and telescope design

1,181

surgical instrument accessories

897

art rock experimentation

679

cosmology and large-scale universe structure

634

ophthalmic diagnostic instruments

614

psychedelic rock soundscapes

536

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

genre-defying rock 695conceptual rock albums 636unconventional rock instruments 585avant-garde rock 566narrative-driven rock 517symphonic rock pieces 494mind-expanding rock 484telescope construction 473

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

accelerating investment in biotech

2 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

astronomical instrumentation and telescope design

1,181 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

1,207 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

reduction in free trade

334 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+14.8% news volume

The latest 12 months contain 3,473 matched records versus 3,024 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

95.0% positive · +4.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 3826 (Laboratory Analytical Instruments). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Laboratory Analytical Instruments Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Agilent leads the readiness ranking

Its Prism readiness score is 49/100, the highest in this five-company comparison.

Open Agilent in Companies Radar

Scale and margin leadership sit with Agilent and Illumina

Agilent has the largest displayed latest revenue at $6.95B; Illumina has the widest displayed latest margin at 19.6%.

Open Agilent in Companies Radar Open Illumina in Companies Radar

Comparisons

Strongest versus weakest available price path

Agilent is -10.1% for its five-year window; 10X Genomics is -63.1% for its five-year window.

Open Agilent in Companies Radar Open 10X Genomics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $6.95B for Agilent to $0.64B for 10X Genomics. Entity and filing-period labels remain visible on the company cards.

Open Agilent in Companies Radar Open 10X Genomics in Companies Radar

Anomalies

Illumina has the widest attention-readiness rank gap

It ranks #1 by measured news attention (62.2%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Illumina in Companies Radar

10X Genomics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +31.1% while its available monthly-close return is -63.1%. The signs differ, but the two measures cover different windows and do not establish causality.

Open 10X Genomics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Illumina's 62.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Illumina in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Agilent's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open Agilent in Companies Radar

Stress-test the largest divergence before forming a view

Compare 10X Genomics's profile with Agilent's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open 10X Genomics in Companies Radar Open Agilent in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.